Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

JAGUAR HEALTH INC

UEI: CFHVVT3L5YZ1CAGE: 9ESE3

JAGUAR HEALTH INC is a federal contractor, registered under UEI CFHVVT3L5YZ1 and CAGE code 9ESE3. It has been awarded $240,100 in federal contracts. Primary work spans Unknown NAICS. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

CFHVVT3L5YZ1

CAGE Code

9ESE3

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit Organization

NAICS Codes

325412Pharmaceutical Preparation Manufacturing(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

JAGUAR HEALTH INC is a biopharmaceutical company focused on the research, development, and commercialization of natural product-derived therapeutics for gastrointestinal and infectious diseases. Their core capabilities center on botanical drug discovery, preclinical pharmacology, and regulatory path...

JAGUAR HEALTH INC is a biopharmaceutical company focused on the research, development, and commercialization of natural product-derived therapeutics for gastrointestinal and infectious diseases. Their core capabilities center on botanical drug discovery, preclinical pharmacology, and regulatory pathway development under FDA’s Botanical Drug Program. The company specializes in isolating, characterizing, and standardizing plant-based active ingredients for clinical application, with expertise in Good Manufacturing Practices (GMP) for botanical extracts, pharmacokinetic modeling, and IND-enabling toxicology studies. A key differentiator is their proprietary platform for enhancing bioavailability and stability of complex phytochemicals, enabling scalable production of consistent, clinically viable formulations. Their work bridges traditional medicine and modern drug development, emphasizing evidence-based validation of ethnobotanical leads. Award history is not available to infer specific agency engagements or contract patterns. Consequently, no definitive relationships with federal agencies can be identified from the provided data. The company operates primarily within NAICS 325412, which encompasses pharmaceutical and medicine manufacturing, specifically focusing on the production of botanical drugs and natural product-based therapeutics. This places them in the niche segment of integrative medicine innovation, where they position themselves as a developer of plant-derived pharmaceuticals meeting stringent regulatory standards for safety, purity, and efficacy. JAGUAR HEALTH INC is structured as a small business (2L) headquartered in San Francisco, California, with no government certifications on record. The company maintains a focused geographic footprint centered on its R&D facilities in California, leveraging the region’s biotech ecosystem for scientific collaboration and talent acquisition. Their market positioning is that of a specialized innovator in natural product drug development, targeting unmet needs in gastrointestinal and tropical disease therapeutics through science-driven botanical discovery.

Key performance metrics

Award counts and award dollars by type, as prime and as subcontractor.

Awards Count

1

All time

Active

0

Currently performing

Completed

1

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award analytics

Awards by agency, industry, year, award type, size, and place of performance.

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with JAGUAR HEALTH INC

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for JAGUAR HEALTH INC

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in JAGUAR HEALTH INC's top NAICS codes and agencies

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
The NIH Small Business Technology Transfer (STTR) grant, solicitation PA-27-102, provides early-stage funding to United States small business concerns (SBCs) to conduct research and development for commercial products in formal collaboration with non-profit research institutions. The program is designed to enhance health and reduce illness through a phased approach: Phase I focuses on establishing technical merit and feasibility, while Phase II advances the research toward commercialization. Eligible applicants include U.S.-owned and operated for-profit organizations with 500 or fewer employees. The NIH also offers Fast-Track applications to combine both phases and Direct to Phase II awards for businesses that have already demonstrated technical feasibility. Funding limits vary by the awarding NIH Institute or Center, with Phase I budgets typically ranging from 400,000 to 700,000 dollars and Phase II budgets reaching up to 3,000,000 dollars. Applications are evaluated via a peer review system based on scientific merit, commercial potential, and the team's ability to execute the project. While clinical trials are generally optional, they require a specific regulatory plan and adherence to strict safety and registration guidelines. Additionally, recipients must maintain active SAM and UEI registrations and comply with federal cybersecurity incident reporting requirements, including notifying the HHS of any breaches within 48 hours.
Department of Health and Human Services

POSTED

5 months ago

DEADLINE

in 5 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
The NIH, CDC, and FDA Small Business Innovation Research (SBIR) Grant, solicitation PA-27-100, provides early-stage funding to United States small business concerns (SBCs) to conduct research and development for commercial products. The program is structured in phases, with Phase I focusing on technical merit and feasibility and Phase II advancing the technology toward commercialization. Eligible applicants include for-profit U.S. businesses with no more than 500 employees. The funding opportunity accepts Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with budget limits varying by participating institute, typically ranging from 400,000 to 700,000 dollars for Phase I and up to 3,000,000 dollars for Phase II. Applications are evaluated through a peer review system based on scientific and technical merit, significance, and the suitability of the business environment. While clinical trials are generally optional, they are prohibited for specific components, including all FDA participating components and several NIH institutes. Recipients must adhere to strict compliance requirements, including maintaining active SAM registration, disclosing foreign relationships, and implementing cybersecurity incident reporting procedures that notify agencies within 48 hours of discovery. The current solicitation remains open for applications until April 6, 2027.
Department of Health and Human Services

POSTED

5 months ago

DEADLINE

in 5 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The SBIR/STTR Commercialization Readiness Pilot (CRP) Program, under solicitation PAR-27-098, is a funding opportunity provided by the National Institutes of Health (NIH) to help U.S.-based small business concerns transition technology from late-stage development to full commercialization. This program specifically targets recipients of prior active or ended NIH SBIR/STTR Phase II or Phase IIB Strategic Breakthrough awards. The CRP supports activities that bridge the gap to market, including late-stage research and development, independent replication of key studies, manufacturing scale-up, and technical assistance such as regulatory strategy, intellectual property planning, and market research. While significant outsourcing to contract research organizations is permitted, the small business must maintain a substantial role in project oversight and management. Eligible projects may have a maximum performance period of three years, with budget ceilings varying by the participating NIH Institute or Center, ranging from 500,000 dollars to 2 million dollars, or following SBA guidelines for certain institutes. Applications are evaluated via the NIH peer review system based on scientific and technical merit, commercial potential, and relevance to program priorities. Key requirements for applicants include maintaining active SAM and UEI registrations and submitting a detailed regulatory plan and progress report. It is important to note that while clinical trials are generally optional, several NIH components, including the NHLBI, NIAID, and NIDDK, do not accept clinical trials under this specific funding opportunity. Additionally, funds cannot be used for patent or FDA filing fees, nor can they include separate Technical and Business Assistance funding.
Department of Health and Human Services

POSTED

5 months ago

DEADLINE

in 5 months
View Details